Decision Benefits Four Million Patients in Pennsylvania and New Jersey
NEWPORT NEWS, Virginia (May 20, 2015) – Effective June 19, 2015, Independence Blue Cross and AmeriHealth, subsidiaries of the Independence Health Group, Inc., a major health insurance company, will provide coverage for use of TheraSkin®, a living cell therapy that effectively treats chronic wounds.
“We are pleased that Independence Blue Cross and AmeriHealth have decided to cover TheraSkin® for their members,” said Allan Staley, CEO of Soluble Systems, LLC, the parent company of TheraSkin®. “We are particularly pleased that TheraSkin® has been approved for use on multiple types of chronic wounds and for very difficult to heal wounds with exposed bone and tendon.”
Staley added; “patients with chronic wounds like diabetic and venous leg ulcers will now have access to the highly effective living cell therapy provided by TheraSkin®. Living cell therapy has been cited as the new “gold standard” of care for these wounds.
Patients who have particularly benefited from the wound healing capabilities of TheraSkin® are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained Staley. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations.” Clinical results show that TheraSkin® effectively closes over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.
About 26 million Americans have diabetes today, expected to be 50 million by 2050. Treating diabetic foot ulcers costs between $9-$13 billion a year. “We will work tirelessly with medical institutions and practitioners in the Independence Blue Cross and AmeriHealth networks to help implement the clinical and economic benefits of TheraSkin®,” said Allan Staley.